✨
AI Summary
- Industry grapples with Most Favored Nation (MFN) policy fallout.
- Rapid early trials accelerate China deals; AbbVie expands neuroscience.
- Regeneron's fianlimab faces setbacks; circular DNA emerges as a potential breakthrough.